A two-year-old male Pointer had been presented with anorexia, cachexia, and weight loss of 10-day duration. Upon physical examination, fever, lethargy, superficial lymph node enlargement, and tick infestation were noted. The only abnormality in CBC and serum chemistry analyses was mild hyperglobulinemia. Spleen was enlarged by radiography, and the lymph nodes showed neutrophilic lymphadenitis by cytological examination. A polymerase chain reaction test for babesiosis and commercial ELISA tests for Ehrlichia canis, heartworm, and Lyme disease was negative except for Lyme disease, which was verified by both an IFA-IgG test and a quantitative C6 assay. Doxycycline was administered for 2 weeks and the recovery was uneventful. Post-treatment C6 titer decreased to within normal limits.
Animals ; Anti-Bacterial Agents/therapeutic use ; Dog Diseases/*diagnosis/drug therapy/epidemiology/pathology ; Dogs ; Doxycycline/therapeutic use ; Enzyme-Linked Immunosorbent Assay/veterinary ; Korea/epidemiology ; Lyme Disease/drug therapy/epidemiology/pathology/*veterinary ; Lymph Nodes/pathology ; Male ; Spleen/radiography

Cancer stem cell (CSC) research has increased exponentially to gain further insight into the mechanisms underlying both carcinogenesis and chemotherapy resistance. The present study was performed to explore the potential value of a side population (SP) assay for identifying and characterizing putative CSCs among canine lymphoma cells. Canine lymphoma cells from cell lines and clinical samples were subjected to the SP assay consisting of Hoechst 33342 staining and subsequent flow cytometric analysis. The SP assay revealed various amounts of a SP fraction among the canine lymphoma cells. The percentages of SP were not affected by inhibitors of membrane transporters, verapamil hydrochloride, or fumitremorgin C. Most of the canine lymphoma cells expressed high levels of Bmi-1 and membrane transporter proteins such as ABCG2 and phosphorylated (p)-glycoprotein. This investigation lays the groundwork for further studies of the biological behaviors and molecular characteristics of CSCs in cases of canine lymphoma.
Animals ; Benzimidazoles/*metabolism ; Cell Line, Tumor ; Dog Diseases/*diagnosis/drug therapy/pathology ; Dogs ; Flow Cytometry/*methods/veterinary ; Fluorescent Dyes/*metabolism ; Gene Expression Regulation, Developmental ; Lymphoma/diagnosis/drug therapy/pathology/*veterinary ; Neoplastic Stem Cells/drug effects/*metabolism/pathology ; Side-Population Cells/drug effects/*metabolism/pathology